Panagis Galiatsatos

Panagis Galiatsatos, M.D., Baltimore, is a pulmonologist who specialized in COPD, asthma, tobacco dependence and health equity.[1]Galiatsatos is the director of the Tobacco Treatment Clinic at Johns Hopkins Medicine.[2]As Johns Hopkins Medicine lung disease expert Galiatsatos , MD, MHS notes , COVID-19 can cause various lung-related complications and long-lasting damage.[3]First of all, according to Galiatsatos, M.D., M.H.S., a lung disease expert at Johns Hopkins Bayview Medical Center, this virus can lead to pneumonia and, in the most severe cases, acute respiratory distress syndrome, or ARDS.[4]Galiatsatos recommends that people find alternative coping mechanisms to treat anxiety during the pandemic.[5]Based on their findings, Galiatsatos and his colleagues recommend that ADI be used to identify vulnerable populations at greatest risk for readmissions following hospitalization for sepsis.[6]

Events - Primer's event detection algorithm clusters and summarizes multiple documents describing real-world events.

Mentions - Mentions are snippets of text that map to a person.

Docs - The number of documents that match to a person in Primer's corpus of news articles.

Full tech explainer here.

Create an article for Panagis Galiatsatos on Wikipedia

Remember to check the sources and follow Wikipedia's guidelines.


  • 6


  • 513


  • 238


Recent events


The National Volunteer Medical Spokesperson Program enters its fourth year with 18 medical professionals from across the United States with expertise in a wide number of lung health topics, from lung cancer, chronic obstructive pulmonary disease, vaping and asthma to healthy air, allergies and quit smoking support. The American Lung Association is the leading organization working to save lives by improving lung health and preventing lung disease, through research, education and advocacy.[1]


Event Date

Smoking and Covid-19: Why young adults are at risk of severe illness

If you were to exclude smokers, only about 16.1 percent of young adults in her study were faced with risk of severe Covid-19. What do we know about smoking and Covid-19? – Adams chose to include vaping in her estimation of risk for young adults because of indications that it may elevate the risk of severe illness.[2]


Event Date

FDA Approves EC-18 for Phase 2 Clinical Trials Targeting ARDS in COVID-19 Patients: Led by Duke Infectious Disease Expert Dr. Cameron Robert Wolfe

South Korean-based Enzychem Lifesciences just announced that the US Food and Drug Administration has accepted its Investigational New Drug Application to evaluate its lead therapeutic candidate EC-18, in a Phase 2 clinical trial in patients with Acute Respiratory Disease Syndrome due to COVID-19 pneumonia. However, if someone develops a cough, fever, and difficulty breathing, this can lead to more severe problems, including a severe or critical condition called acute respiratory distress syndrome.[3]


Event Date